Elanco Animal Health (NYSE: ELAN) reported Q2 EPS of $0.09, $0.03 better than the analyst estimate of $0.06. Revenue for the quarter came in at $586.3 million versus the consensus estimate of $589.43 million.

FINANCIAL GUIDANCE

• For the third quarter of 2020, legacy Elanco Total Revenue is expected to be between $660 and $710 million. Core Revenue, excluding Strategic Exits, is expected to be between $650 and $700 million, including our estimate of approximately $30 to $50 million in COVID-19 related headwinds. Elanco will divest a limited number of products in conjunction with the close of the Bayer Animal Health transaction. Revenue from divested products is expected to represent between $12 and $20 million for two months of the quarter and has been excluded from the total Revenue and Core Revenue estimates.

For earnings history and earnings-related data on Elanco Animal Health (ELAN) click here.